Phase I, Open-Label, Randomized, Single Sequence Study With Two Dose Groups to Compare the Pharmacokinetics of BMS-927711 in Migraine Subjects During an Acute Migraine Attack and During Non-Migraine Period.
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Rimegepant (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Pharmacokinetics
- Sponsors Biohaven Pharmaceutical Holding Company
- 07 Jun 2013 Actual initiation date changed from Jan 2011 to Nov 2011 as reported by ClinicalTrials.gov.
- 30 Mar 2012 Planned End Date changed from 1 Mar 2012 to 1 Jun 2012 as reported by ClinicalTrials.gov.
- 15 Feb 2012 Actual initiation date changed from Nov 2011 to Jan 2011 as reported by ClinicalTrials.gov.